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bjectives This study sought to assess the safety and efﬁcacy of transcatheter valve annuloplasty in
atients with mitral regurgitation (MR).
ackground Mitral regurgitation is associated with a worsened prognosis in patients with dilated
ardiomyopathy. Surgical mitral annuloplasty reduces the septal-lateral dimension of the mitral an-
ulus resulting in improved leaﬂet coaptation with a reduction in regurgitation. Percutaneous annu-
oplasty with the MONARC device (Edwards Lifesciences, Irvine, California) implanted within the cor-
nary sinus is designed to reduce mitral regurgitation through a similar mechanism.
ethods A total of 72 patients with MR grade 2 were enrolled at 8 participating centers in 4
ountries. Clinical evaluation and transthoracic echocardiography were performed at baseline and at
, 6, and 12 months. Multislice cardiac computed tomography and coronary angiography were per-
ormed at baseline and 3 months.
esults The MONARC device was implanted in 59 of 72 patients (82%). The primary safety end
oint (freedom from death, tamponade, or myocardial infarction at 30 days) was met in 91% of pa-
ients at 30 days and in 82% at 1 year. Computed tomography imaging documented passage of the
reat cardiac vein over an obtuse marginal artery in 55% of patients and was associated with angio-
raphic coronary artery compression in 15 patients and myocardial infarction in 2 patients (3.4%). At
2 months, a reduction in MR by 1 grade was observed in 50.0% of 22 implanted patients with
atched echocardiograms and in 85.7% of 7 patients with baseline MR grade 3.
onclusions Implantation of the MONARC device in the coronary sinus is feasible and may reduce
R. However, coronary artery compression may occur in patients in whom the great cardiac vein
asses over a coronary artery, necessitating strategies in future studies to avoid this occurrence.
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116unctional mitral regurgitation (MR) frequently develops in
atients with heart failure and a dilated left ventricle due to
apillary muscle displacement, leaflet tethering, and pro-
ressive mitral annular dilation. This may lead to a vicious
ycle of worsening heart failure and MR. Late prognosis is
etermined, in part, by the severity of MR (1–3).
Treatment options for functional MR are limited. Phar-
acological therapy and resynchronization pacing may re-
uce MR and improve outcome in selected patients (1,4,5).
lthough surgical repair of the mitral valve may reduce MR,
ortality and morbidity are significant and recurrence is
ommon (6,7). Patients with MR have a poor prognosis
espite medical, resynchronization, or surgical therapy (8–12).
onsequently, there is considerable interest in lesser invasive
pproaches to treat MR in patients with ischemic and dilated
ardiomyopathy.
We recently reported our initial experience with a first-
eneration catheter-based coronary sinus (CS) device de-
igned to address MR (13). We now report the safety and
fficacy of a modified second-generation device in patients
with clinical and echocardio-
graphic follow-up for 1 year.
Methods
Patient selection. Patients were
eligible if they had heart failure
and dilated cardiomyopathy (isch-
emic or idiopathic) with MR
grade 2 (on a scale of 0 to 4)
as assessed by color flow criteria
on transthoracic echocardiogra-
phy. Coronary sinus anatomy
was considered suitable for the
ONARC device if the proximal anterior interventricular
ein (AIV) was 3 mm and 6 mm in diameter, the ostial
S was 7 mm and 16 mm in diameter, and the length
rom the great cardiac vein (GCV) to the ostial CS was14
m and 18 cm.
Exclusion criteria included structural valve disease includ-
ng endocarditis, rheumatic disease, or moderate-to-severe
itral valve prolapse. Patients with pre-existing implantable
efibrillators, CS leads for biventricular pacing, left ventric-
lar ejection fraction 25%, prior percutaneous coronary
ntervention within 3 months, moderate-to-severe mitral
nnular calcification, serum creatinine 2.0 mg/dl, or in-
bility to comply with all protocol procedures were also
xcluded. Patients received aspirin 180 to 325 mg and
lopidogrel 300 mg before the procedure and continued on
aily doses of aspirin 81 mg indefinitely and clopidogrel
5 mg for 3 months. Written informed consent and hospital
thics committee approval were required.
evice description. The MONARC system consists of a
bbreviations
nd Acronyms
IV  anterior
nterventricular vein
S  coronary sinus
T  computerized
omography
CV  great cardiac vein
I  myocardial infarction
R  mitral regurgitation
YHA  New York Heart
ssociation2-F guide catheter and dilator, a 9-F delivery catheter, and pnickel-titanium alloy (nitinol) implant. The implant has 3
ections: a distal self-expanding anchor, a springlike
bridge,” and a proximal self-expanding anchor. The distal
nchor is deployed at the transition between the AIV and
he GCV; the proximal anchor is deployed in the ostial CS
Fig. 1). The anchors are designed such that they remain
rmly in place acutely and encourage tissue in-growth,
hich provides a secure platform at both ends of the device.
biodegradable component is incorporated within the
pringlike bridge and maintains the device in an elongated
tate at the time of implantation. After implantation, the
iodegradable element absorbs over approximately 1 month,
reating an active and sustained spring tension between the
nchors. Shortening of the device is designed to reduce the
eptal-lateral dimension of the mitral valve and thereby
mprove leaflet coaptation (Fig. 1).
The first-generation MONARC device developed a frac-
ure in the bridge segment that resulted in device separation
uring follow-up in 3 of 5 patients (13). Bridge separation
id not cause adverse events but may have reduced the
fficacy of the device. Therefore, a nonbiodegradable suture
as added to reinforce the bridge segment and reduce the
ikelihood of separation of the device following implanta-
ion. This second-generation MONARC device was tested
n the present study. Available device sizes during this study
anged in length from 120 to 159 mm, with proximal and
istal anchor diameters of 10 to 18 mm and 6 to 8 mm,
espectively.
mplant procedure. The internal jugular vein is accessed
ercutaneously and a guiding catheter used to cannulate the
S (13). A steerable guidewire is advanced to the AIV over
hich a calibrated angiographic catheter (Cook Medical
nc., Bloomington, Indiana) is placed to facilitate measure-
ent of the coronary venous anatomy. A MONARC device
s selected with anchors 2 to 4 mm larger in diameter than
he proximal AIV and CS and a length 2 cm shorter than
he distance between these 2 sites. The MONARC delivery
atheter is advanced over the guidewire and through the
uiding catheter. The distal anchor is deployed at the
unction of the AIV and GCV by retracting the outer
estraining sheath. The device is tensioned slightly to
emove slack, following which the sheath is retracted further
o release the proximal anchor.
tudy end points. The primary safety end point was the
reedom from the composite occurrence of death, tampon-
de, or myocardial infarction (MI) at 30 days. A secondary
afety end point was freedom from the composite occur-
ence of device embolization or migration from the target
rea, death, MI, CS thrombosis, or pulmonary embolism at
months. The primary efficacy end point was procedural
uccess, defined as device deployment at the intended
ocation without the occurrence of serious adverse events
death, tamponade, or MI). The secondary efficacy end
oint was a reduction in mitral regurgitation by 1 grade.
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117atients were followed at discharge and at 1, 3, 6, and 12
onths.
maging and core laboratory analysis. An electrocardiogram
as obtained before and after the implant procedure.
ransthoracic echocardiography was performed before the
mplant, at discharge, and at 1, 3, 6, and 12 months of
ollow-up. Transesophageal echocardiography was per-
ormed before the implant and at 3-month follow-up and
nalyzed at a core laboratory (Cardiovascular Research
nstitute, Washington, D.C.). Coronary angiography was
erformed before the implant procedure and at 3-month
ollow-up and analyzed at a core laboratory (University of
olorado Health Science Center, Denver, Colorado).
omputerized tomographic (CT) scans were performed
efore and 3 months after the implant procedure and
nalyzed at a core laboratory (Ohio State University Med-
cal Center, Columbus, Ohio). Chest X-rays were obtained
t discharge and at 1, 6, and 12 months of follow-up.
reatine kinase, creatine kinase-myocardial band, and tro-
onins were measured after the procedure and as indicated
or suspicion of recurrent ischemia.
tatistical methodology. Analysis of safety end points was
erformed in all patients. Analysis of efficacy was performed
nly in patients with implanted devices. Paired t tests and
A
Figure 1. The Mode of Action of the MONARC Device
The MONARC device encircles the posterior leaﬂet of the mitral valve in systol
in the anterior interventricular vein, the springlike bridge section is positioned
ostium of the coronary sinus. The bridge section shortens during the ﬁrst mon
tal-lateral diameter of the mitral annulus with improved coaptation of the le
CS  coronary sinus; GCV  great cardiac vein.ilcoxon signed rank tests were used to assess the differ- 3nces from baseline to follow-up of continuous and ordinal
ariables, respectively. A p value of 0.05 was considered
ignificant.
esults
aseline features and implantation procedures. A total of 72
atients were enrolled between October 2005 and March
007 at 8 participating centers in Canada, France, Ger-
any, and Sweden. The mean age was 70.0  9.8 years
range 37 to 90 years); 20 (18%) were women. Diabetes was
resent in 17 patients (24%), hypertension in 39 (54%), and
ypercholesterolemia in 39 (54%). Most patients (68%) had
nderlying coronary artery disease, as manifested by a
istory of prior MI (57%), and/or coronary arterial bypass
raft (47%) and/or percutaneous coronary intervention
40%). The baseline New York Heart Association (NYHA)
lass was I in 4%, II in 42%, III in 50%, and IV in 4%. The
ean left ventricular ejection fraction was 37.8  10.7%
range 23% to 67%). Mitral regurgitation at baseline as
ssessed by the core laboratory (transthoracic echocardiog-
aphy in 59 patients and transesophageal echocardiography
n 13 patients) was grade 1 in 8%, grade 2 in 54%, grade
B
plant (A) and in its activated state (B). The small distal anchor is positioned
great cardiac vein, and the large proximal anchor is positioned in the
er implantation. The putative mechanism of action is a reduction of the sep-
and a reduction in mitral regurgitation. AIV  anterior interventricular vein;e at im
in the
th aft
aﬂets in 21%, and grade 4 in 17%.
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118The device was implanted in 59 of 72 patients (82%). In
he other 13 patients, a device was not implanted due to
xcessive tortuosity of the coronary venous anatomy or the
ack of appropriately sized devices. In 1 of the patients with
tortuous sinus, there was an intraprocedural small dissec-
ion of the sinus during guidewire manipulation. The case
as abandoned. Post-procedural echocardiography confirmed
o pericardial effusion. Procedure time was 84  59 min.
ospital stay was 4.1  4.7 days.
dverse events. Among the 72 enrolled patients, the pri-
ary safety end point of freedom from the occurrence of
eath, tamponade, or MI at 30 days was 91% at 30 days and
2% at 12 months. The secondary safety end point was
chieved in 87% of patients at 3 months, 83% at 6 months,
nd 81% at 1 year.
Major adverse cardiovascular events are summarized in
able 1. Coronary sinus perforation resulted in 2 cases of
amponade early in the study from use of a stiff straight
ipped wire; this complication did not recur with a change to
-tipped guidewires. Following discharge, MI occurred in 2
atients. One patient presented at day 16 with compression
f a diagonal artery by the distal anchor. A second patient
resented at day 19 with compression of an obtuse marginal
rtery. This site was stented with patency documented at
-year follow-up.
There were no in-hospital deaths. None of the late deaths
8) were attributable to the procedure or device (Table 1).
he survival rate was at 97%, 92%, 89%, and 87% at 1, 3, 6,
nd 12 months, respectively. Other adverse secondary safety
nd point events through 1-year follow-up included
Table 1. Major Adverse Cardiovascular Events at 1 Year
Event Cause
Tamponade (n  2)
Day 1 Wire perforation*
Day 6 Wire perforation*
Myocardial infarction
(n  2)
Day 16 Diagonal artery compression due to distal anchor
Day 19 Obtuse marginal artery compression due to bridge
Death (n  8)
Day 22 Arrhythmia (intractable ventricular ﬁbrillation)
Day 24 Heart failure
Day 51 Sudden cardiac death while being treated for
erysipelas
Day 52 Fall leading to intracranial hemorrhage
Day 61 Pulmonary embolism
Day 96 Multiorgan system failure following post mitral valve
surgery
Day 141 Heart failure
Day 280 Heart failure
*Non–J-tipped wire used.ulmonary embolism in 1 patient and device migration inpatient. There were no cases of device embolization or
S thrombosis.
evice malfunctions and coronary compressions. Routine
ollow-up coronary angiography at 3 months in 50 of 59
mplants revealed 4 cases (8%) of separation of the bridge
rom the proximal anchor. No adverse clinical events were
ssociated with anchor separation. However, only 1 of these
patients had an improvement in the degree of MR
compared with baseline) at follow-up.
Of 50 patients with implanted devices in whom
ollow-up angiography was performed, some degree of
oronary artery compression was noted in 15 patients (30%):
were distal anchor-related, 9 were bridge-related, and 1
atient had both. The stenosis severity assessed by the
ngiographic core laboratory was 50% in 4 patients (8%)
Table 2). Among the 15 patients with angiographic coro-
ary artery compression, 2 (13.3%) suffered a myocardial
nfarction.
Core laboratory analysis of CS anatomy by CT was
vailable in 42 patients. The CS/GCV was observed to pass
ver a major obtuse marginal artery in 23 patients (55%), 8
f whom (34.8%) had angiographic coronary artery com-
ression. In contrast, the CS/GCV did not pass over a
ajor obtuse marginal artery in 19 patients, none of whom
eveloped coronary compression.
fﬁcacy analysis. Among the 59 patients in whom a device
as implanted, the in-hospital procedural success rate was
3% (n  55). In 4 patients, the proximal anchor was
eleased outside the intended range of 0.5 to 2 cm from
he CS ostium. Although this was not associated with
dverse events, only 1 of these 4 patients had a reduction in
R at last follow-up. The secondary end point occurred in
7% of patients at 3 months, 83% at 6 months, and 81% at
year (Fig. 2).
Table 2. Patients With Coronary Arterial Compression. Quantitative
Angiographic Analysis Through 12 Months
Patient #
Vessel Diameter
Baseline (mm)
Stenosis
Baseline (%)
Stenosis
90 Days (%)
102 3.1 0 30
258 3.1 1 31
259 3.7 0 42
007 2.5 10 44
121 2.3 17 45
053 0.9 37 100
019 1.3 20 48
006 1.8 19 79
119† 2.1 17 99
256‡ 1.2 59 100
*Occlusion of a diagonal artery documented at day 16. This appeared due to compression by an
anchor in the anterior interventricular vein. Spontaneously recanalized at day 90. †Occlusion of
an obtuse marginal artery at day 19. Presented with acute myocardial infarction. Successfullystented. ‡Occlusion of a small obtuse marginal artery. No clinical event.
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119The secondary efficacy end point (responder rate) is
isplayed in Figure 3 for 22 patients with matched data, in
hom all transthoracic echocardiograms were completed
ithin the pre-specified protocol windows (the results when
ll unmatched data were included were comparable—data
ot shown). In these 22 patients, the mean grade of MR was
.5  0.7 at baseline and 1.8  0.8 at 12 months (p 
.002). Mitral regurgitation decreased by 1 grade from
aseline to follow-up in 40.9% of patients at 3 months and
n 50.0% of patients at 6 months and 1 year. Moreover, the
esponse rate appeared to be higher in the 7 patients with
aseline grade 3 MR compared with the 15 patients
ith only grade 2 MR at baseline. The responder rate at
2 months was 85.7% in patients with severe MR at
aseline (grade 3) in whom the mean MR grade was
educed from 3.4  0.5 at baseline to 2.1  0.9 at last
ollow-up. Significantly fewer patients with a baseline MR
rade of 2 responded (Fig. 3).
ffects on left ventricular structure and function. Serial
hanges in quantitative echocardiographic variables are
hown in Table 3. Although not powered or tested for
tatistical significance, directional reductions were present
rom baseline to follow-up in mitral valve annular diameter,
ffective regurgitant orifice area, regurgitant volume, left
trial volume, left ventricular end diastolic volume, left
entricular end systolic volume, and left ventricular ejection
raction.
hanges in NYHA functional class. In the paired analysis, 26
f 47 surviving patients at 6 months (55.3%) had at least 1
YHA functional class improvement (including 12 patients
ho were NYHA class I), and 5 patients improved by at least
NYHA classes. NYHA functional class progressed at 6
Number at risk 72 57 51 45 35
72 59 51 45 35
Kaplan-Meier Curves
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Figure 2. Probability of Event-Free Survival After MONARC Implantation
Kaplan-Meier curves for freedom from the composite occurrence of death,
tamponade, or myocardial infarction and freedom from the composite
occurrence of device embolization or migration from the target area,
death, myocardial infarction, coronary sinus thrombosis, or pulmonary
embolism.onths in only 2 patients. At 12 months, 19 of 41 survivingatients (46.3%) had at least 1 NYHA class improvement
including 9 patients in NYHA class I), and 6 patients
mproved by at least 2 NYHA classes. Only 1 patient had
unctionally deteriorated.
ther late clinical events. Five patients who did not have a
linically adequate reduction in MR following MONARC
evice implantation subsequently underwent mitral valve
urgery at days 70, 110, 164, 222, and 232, respectively (ring
nnuloplasty in 2 patients and mitral valve replacement in 3
atients). Surgery was not influenced by the presence of the
tudy implant. One patient died after surgery from multi-
rgan failure, and 4 patients had an uncomplicated post-
perative course with significant reduction in MR.
Five patients who had persistent heart failure subse-
uently underwent implantation of a coronary sinus lead for
iventricular pacing at days 109, 149, 170, 222, and 357
fter device implantation. The placement of the lead was
ot hampered by the presence of the MONARC implant
14) and served as a convenient landmark for the CS ostium.
iscussion
he 12-month results of the multicenter prospective, non-
andomized EVOLUTION phase I trial (Clinical Evaluation
f the Edwards Lifesciences Percutaneous Mitral Annuloplasty
ystem for the Treatment of Mitral Regurgitation) demon-
trate the feasibility of a gradually foreshortening indirect
cting mitral annuloplasty system delivered into the coronary
inus via a percutaneous jugular venous approach to reduce
R in patients with dilated and ischemic cardiomyopathy.
ompared with other percutaneous mitral valve repair tech-
ologies, the MONARC procedure is relatively straightfor-
85.7%
50.0%
33.3%
85.7%85.7%
50.0%
40.9%
33.3%
20.0%
0%
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20%
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%
 R
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Baseline MR 3+ & 4+
(n=7) 
Baseline MR 2 - 4+
(n=22)
Baseline MR 2+
(n=15)
Figure 3. 1-Year Echo Outcome of MR Severity
Percentage of patients with improvement in mitral regurgitation by 1
grade. Serial paired transthoracic echocardiograms in patients with com-
plete data (squares, n  26), with baseline mitral regurgitation grade 3
(triangles), and with baseline regurgitation grade 2 (diamonds).
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120ard and has a short learning curve and procedure time. A
ajority of patients appeared to have a reduction in MR during
ollow-up, with the percentage of responders gradually increas-
ng from baseline to 6 months and thereafter stabilizing.
atients with severe MR (grade 3) seemed most likely to
enefit.
Major procedural complications included 2 cases of CS
erforation occurring due to navigation of the GCV in the
arly phase of the trial with a straight-tip guidewire.
owever, the potential for external coronary artery com-
ression when the CS/GCV runs over the obtuse marginal
picardial vessels (which occurs in 50% of patients [15])
merged as the most important consideration for use of this
evice. Angiographic follow-up demonstrated some degree
f coronary artery narrowing in 30% of patients, which was
ignificant (diameter stenosis50%) in 8% of patients. This
esulted in coronary occlusion in 3 patients, 2 of whom
resented with a MI (3.4% of all patients receiving an
mplant). Patients in whom the anatomic relationship of the
oronary venous and arterial anatomy is not a concern may
Table 3. Serial Quantitative Echocardiographic Measurements
Time
n Baseline Follow-Up %  p
Mitral Valve Annular Diameter (cm)
Discharge 46 3.61 0.42 3.51 0.42 3%
1 month 43 3.57 0.39 3.50 0.37 2%
3 months 35 3.54 0.37 3.42 0.42 4%
6 months 35 3.61 0.40 3.36 0.45 7%
12 months 27 3.62 0.42 3.32 0.39 9%
Left Ventricle Ejection Fraction (%)
Discharge 29 37.4 10.9 39.1 10.6 4%
1 month 32 37.2 10.6 38.6 12.2 4%
3 months 34 34.8 9.9 35.5 10.1 2%
6 months 34 36.2 10.4 37.5 9.2 3%
12 months 26 36.8 9.9 40.2 8.3 8%
Left Ventricle End-Systolic Volume (ml)
Discharge 29 109.9 44.9 104.3 50.2 5%
1 month 32 111.3 56.3 102.8 46.2 8%
3 months 34 118.4 50.0 111.2 41.8 6%
6 months 34 116.0 54.7 111.6 53.4 4%
12 months 26 114.8 56.8 98.2 37.9 17%
Time n Baseline
Discharge 27 129.2 65.0
1 month 33 113.2 52.0
3 months 33 102.9 43.5
6 months 34 104.4 43.7
12 months 27 101.5 28.6
EROA estimated regurgitant orifice area.nclude those with small, occluded, or protected (patent wypass graft) circumflex branches. The present study has
lso demonstrated that noninvasive screening with CT is
ble to identify those patients in whom the obtuse marginal
essels course under the CS/GCV who are at risk. None-
heless, if the potential safety benefits of the MONARC are
o be realized, prospective studies are required to demon-
trate that procedural and late complications can be avoided.
Whether the gradual nature of MONARC device acti-
ation is beneficial compared with acute CS tensioning (16)
annot be answered by this study. The constant and con-
inuous foreshortening of the device over 4 to 6 weeks may
llow the heart to progressively remodel. The observation
hat left ventricular structure and function continued to
mprove between 3 and 6 months (well after which maximal
evice contraction has occurred) suggests that the gradual
eduction in MR in patients might interrupt the progressive
ycle of increasing heart failure and MR, although con-
rolled studies in greater numbers of patients are required to
onfirm this hypothesis. Finally, compared with other CS
echnologies, the greater length of the MONARC device
n Baseline Follow-Up %  p Value
EROA (cm2)
20 0.31 0.23 0.25 0.19 24% 0.01
18 0.27 0.20 0.25 0.17 8% 0.39
25 0.23 0.18 0.19 0.13 21% 0.12
26 0.24 0.18 0.17 0.15 41% 0.03
19 0.22 0.11 0.16 0.10 38% 0.12
Regurgitant Volume (ml)
21 40.4 24.6 31.6 20.3 28% 0.01
18 37.7 20.9 31.5 16.8 20% 0.14
25 33.7 21.9 28.6 16.6 18% 0.27
25 34.6 21.9 23.2 14.3 49% 0.02
19 31.8 16.1 25.0 15.1 27% 0.14
Left Ventricle End-Diastolic Volume (ml)
29 170.1 54.7 165.1 64.4 3% 0.26
32 170.6 71.0 163.3 62.0 4% 0.23
34 175.8 60.6 169.8 57.7 4% 0.36
34 175.4 68.2 173.9 74.5 1% 0.83
26 175.4 72.5 161.9 54.8 8% 0.05
Left Atrial Volume (ml)
Follow-Up %  p Value
127.3 65.1 1% 0.69
119.4 50.4 5% 0.14
102.7 44.5 0% 0.95
100.1 56.1 4% 0.37
98.9 26.9 3% 0.53Value
0.01
0.16
0.05
0.01
0.01
0.12
0.29
0.59
0.29
0.08
0.08
0.20
0.25
0.44
0.02ith placement of the distal anchor in the AIV may be
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121mportant for left ventricular remodeling, as it tends to lift
r retract the anterior wall of the ventricle.
Ventricular systole results in significant torquing and
ending of CS implants. Bridge fractures with separation,
hich occurred with the first-generation device (13), were
ot observed in the present study, attesting to the success of
esign modifications. However, fractures in the proximal
nchor were noted in 4 patients in the present series, which
ay have contributed to lack of device efficacy. Extending
he bridge-section reinforcement to this region of the device
ay reduce this fracture mode.
Importantly, MONARC device implantation did not ap-
ear to interfere with subsequent mitral valve surgery (n  5)
r CS lead placement (n  5). One patient had previously
ndergone a Mobius (Edwards Lifesciences) clip implant (17)
an investigational device that used a percutaneous suture to
chieve a double outlet mitral valve) and was additionally
reated with the MONARC device 3 months later without
ifficulty. Surgical experience suggests that mitral annuloplasty
nd edge-to-edge leaflet repair (18) may be synergistic in the
reatment of MR.
Additional studies are required to determine the echocar-
iographic and clinical benefits that may be achieved with
he present device. The average 1-grade reduction in MR
ith the MONARC device is less than what is obtained
ith surgical mitral valve repair, but may be of some benefit
n patients with functional MR, particularly if accomplished
ith minimal periprocedural morbidity. Moreover, patient
nclusion and exclusion criteria may affect the likelihood of
favorable response. The response rate was highest in the
atients with more severe grades of MR. More sophisticated
chocardiographic assessment may provide additional in-
ight into which patients are likely to benefit with a CS
nnuloplasty device (1). Surgical series have suggested that
mproved cardiac performance after mitral valve repair
ccurs only when the pre-operative left ventricular end
iastolic diameter is 65 mm (19).
tudy limitations. The present report is the largest study to
ate of CS annuloplasty. Nonetheless, limitations of this
hase I study include the modest sample size, heterogeneity
f the study population, incomplete follow-up, and lack of a
ontrol group. Analyzable echocardiographic quantitative
arameters were not available from all patients at all times.
unctional measures of heart failure improvement such as
he 6-min walk time and quality-of-life measures beyond
YHA class were not assessed.
onclusions
he limitations notwithstanding, the present study indi-
ates that implantation of the MONARC device in patients
ith functional MR is feasible, can be performed at rela-
ively low procedural risk, and may result in a reduction in
R. However, coronary artery compression may occur inatients in whom the CS/GCV courses over the circumflex
essels and may result in late MI. A multicenter evaluation
f the MONARC device (EVOLUTION II) is underway
o determine the safety and efficacy of this device (with a
einforced proximal anchor) in patients with MR. This
tudy includes pre-procedural CT screening to exclude
hose at risk for coronary compression of a major epicardial
essel, a concurrent control group, and serial measures of
-min walk time and quality of life. Ultimately, a random-
zed controlled trial will be necessary to establish a potential
ole of the MONARC device in the treatment of patients
ith MR.
eprint requests and correspondence: Dr. Jan Harnek, Depart-
ent of Coronary Heart Disease, Skane University Hospital,
und, Lund University, Getingev, SE-22185 Lund, Sweden.
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or a description of the EVOLUTION I study organization and list of
articipants, please see the online version of this article.
